Accelerated Venture Partners consists of a team, capable of creating a unique system of financial, operational and management expertise. Led by Timothy Neher , our management team has over a fifty years in combined experience in management, financial researching, and small to large market transactions to provide our prospects a guided path to success.
Mr. Neher is the founding partner of Accelerated Venture Partners, LLC, and has over 20 years of experience in connection with the provision of debt and equity financing, mergers and public offering transactions. Timothy has been on the Board of Directors for Virolab, Inc., a public reporting company since 2010 and the acting Chief Financial Officer, Treasurer and a Director of Mikojo, Inc. a public reporting company since 2010 and a Director of Greentech Mining International, Inc. a public reporting company since 2012. Mr. Neher is also Director of Pinpointed Solutions Inc. a private company since 2008, Director of Ipaypod Inc., a private company since 2007 and Director of Internet Card Present, Inc., a private company since 2007. He is also the President, Secretary and sole director of following public reporting companies: Accelerated Acquisitions XVII, XIX. Within the past five years Mr. Neher has been the founder of the following public reporting companies, Accelerated Acquisitions I, II, III, IV, V, X, XI, XII, XIII, XIV, XV, XVI,XVIII, XX, XXI and XXII. Prior to founding Accelerated Venture Partners, Internet Card Present Industries, Pinpointed Solutions, Ipaypod and the public companies above, Timothy was Chairman and Chief Executive Officer of Wherify Wireless, a private to public company from 1999 to 2007. Mr. Neherís past experience at Wherify involved raising an estimated $200 million dollars and negotiating global contracts with GE, Seimens, Qualcomm, Uniden, Flextronics and other fortune 500 companies.
Charles P.R. de C. du Mée, PhD, MBA
Charles has 25 years of pharmaceutical and biotechnology experience. Charles was a co-founder, Director and Vice President of Nascent Pharmaceuticals. Prior to Nascent, Charles was at COR Therapeutics, (acquired by Millennium Pharmaceuticals for $2 billion), he was Vice President of Technical Operations and previously held the position of Vice President of Product Development. His responsibilities during his 12 years at COR included analytical, process and pharmaceutical development, quality control and contract manufacturing for clinical and commercial products. He helped develop COR’s lead product, Integrilin®, from lead compound to a product with over $300 million in annual sales. Prior to joining COR in 1990, Charles spent four years at Genentech, where he contributed to numerous regulatory documents and two years at Monsanto Company. Charles has a Ph.D. in Biochemistry and Molecular Biology from the University of Florida., an MBA from the University of San Francisco, and he received both a B.Sc. in Chemistry and Biochemistry and a B.Sc.Hons. in Biochemistry from the University of Natal, South Africa.